Open AccessExpression of Tumor‐associated Glycoantigen, Sialyl Lewis a , in Human Head and Neck Squamous Cell Carcinoma and Its Application to Tumor Immunotherapy
Author(s) -
Makino Koji,
Ogata Tetsuro,
Miyake Hirosato,
Habu Sonoko,
Nishimura Takashi
Publication year - 1994
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1994.tb02964.x
Subject(s) - immunotherapy , head and neck squamous cell carcinoma , head and neck , epidermoid carcinoma , medicine , pathology , cancer research , carcinoma , lewis lung carcinoma , basal cell , head and neck cancer , cancer , metastasis , surgery
The glycoantigen sialyl Lewis a (sLe a ) is widely expressed on a variety of gastrointestinal tumor cells. Here, we immunohistochemically demonstrated the expression of sLe a antigen in 54% (7 out of 13) of human head and neck squamous cell carcinoma (H‐NSCG) samples. Frequent expression of sLe a antigen was also demonstrated on a variety of H‐NSCC cell lines using flow cytometry. Both CD4 + and CD8 + T cells, which were activated with immobilized OKT3 monoclonal antibody plus inter‐leukin‐2, showed augmented cytotoxicity against sLe a ‐positive H‐NSCC, including autologous tumor cells, on targeting with anti‐CD3 x anti‐sLe a bispccific antibody, suggesting that sLe a antigen is a good target molecule for bispecific antibody‐dependent adoptive tumor immunotherapy of human head and neck cancer.